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PORCINE SOMATOTROPIN TO IMPROVE MEAT 
QUALITY OF PIGS 
stress syndrome are administered a small amount of 
porcine somatotropin during their period of most rapid 
weight gain the muscle quality is significantly im-
proved, and in particular is equal to the muscle quality 
BACKGROUND OF THE INVENTION 5 of non-stress genotypes. This indicates that the porcine 
somatotropin treatment ameliorates the negative effect 
of stress on muscle quality. 
It is known that certain genotypes of swine are more 
susceptible to porcine stress syndrome than others. In 
swine breeding, raising and production, problems asso-
ciated with porcine stress syndrome are a very real 
concern. The concern is present because swine suffering 10 
from porcine stress syndrome do not perform as well 
from the standpoint of efficiency of weight gain, quality 
of meat, and of course profitability. There is, therefore, 
a need and a continuing effort to develop methods of 
treating animals susceptible to porcine stress syndrome 15 
so that these animals can be effectively and profitably 
raised. 
The fact that these animals are normally intended for 
ultimate slaughter and consumption by humans raises 
several associated problems. In particular, any drugs 20 
used must be demonstrated to be safe and efficacious 
and to have no ultimate impact on the general edible 
quality of the animal's meat. This, of course, eliminates 
some drug treatments which could otherwise be used 
with swine to treat porcine stress syndrome. Also, it is 25 
very important from the standpoint of consumer accept-
ability of the meat product that any treatment for por-
cine stress syndrome not effect the muscle quality of the 
animal's meat. In particular, swine suffering from por-
cine stress syndrome often have pale, soft and exudative 30 
meat. Of course, if the meat or muscle is pale in color, 
soft, spongy and exudative, regardless of taste and fla-
vor, it will not be accepted and purchased by consum-
ers. 
There is, therefore, a real and continuing need for a 35 
way to treat certain genotypes of swine normally sus-
ceptible to porcine stress syndrome such that muscle 
quality problems of the animal often associated with 
porcine stress syndrome are alleviated. 
There is also a continuing need for such a treatment 40 
as mentioned above, which in no way adds adulterating 
drug levels to the meat. Further, there is a continuing 
need for a way of treatment of genotypes of swine nor-
mally susceptible to porcine stress syndrome so that the 
meat of the animals will not be pale, soft and exudative. 45 
Accordingly, it is a primary objective of the present 
invention to provide a treatment for genotypes of swine 
normally susceptible to porcine stress syndrome, which 
alleviates muscles quality problems normally associated 
with porcine stress syndrome. 50 
Another objective of the invention is to provide a 
method of treatment which provides no adulterating 
drug levels in the meat. 
A further objective of the present invention is to 
provide a treatment which when given to genotypes of 55 
swine normally susceptible to porcine stress syndrome 
minimizes the tendency of the muscle to be pale, soft 
and exudative. 
The method and manner of accomplishing each of the 
above objectives will become apparent from the de- 60 
tailed description of the invention and the examples 
which follow. 
SUMMARY OF THE INVENTION 
This invention involves the application of porcine 65 
somatotropin to alleviate muscle quality problems asso-
ciated with porcine stress syndrome. In particular, if 
genotypes of swine normally susceptible to porcine 
DETAILED DESCRIPTION OF THE 
INVENTION 
In accordance with this invention, porcine somato-
tropin is administered on a daily basis to animals, in 
conjunction with their intake of their normal feed ra-
tion. Porcine somatotropin, or porcine growth hormone 
(pGH) is a known natural materials, and can be ex-
tracted from the animal itself. Alternatively, porcine 
growth hormone can be prepared by using recombinant 
DNA technology to prepare recombinantly derived 
analogs of porcine somatotropin. For examples of tech-
niques of preparing recombinant DNA derived analogs 
of porcine somatotropin see U.S. Pat. No. 4,766,224 of 
Rausch, issued Aug. 23, 1988, which is incorporated 
herein by reference. 
In accordance with the process of the present inven-
tion, both naturally extracted porcine growth hormone 
or recombinant DNA technology produced porcine 
somatotropin may be used in the process of this inven-
tion. As a practical matter, recombinant DNA technol-
ogy produced porcine somatotropin is the most eco-
nomical, and therefore the preferredsource. Briefly, in 
the process of preparing pGH, by recombinant DNA 
technology, pGH is cloned onto expression vectors and 
used to transform E. coli host cells. The pGH is then 
grown in the E. coli host cell, and can thereafter be 
lysed from the cells, separated from the remainder of 
the cellular material, isolated and segregated for use. 
In accordance with this invention, the animals which 
are normally susceptible to porcine stress syndrome are 
provided with daily dosages of the pGH during their 
period of time for critical weight gain, namely from 
when they are just out from starter pig phase up to 
slaughter time. Generally this runs from about the 
weight of 120 pounds, up to a slaughter weight of 240 
pounds. Timewise, this generally means from a period 
of about three months up to about five to six months of 
age. If the porcine somatotropin is administered earlier 
in life less dramatic affect is seen. Likewise, if adminis-
tration begins much later than about 120 pounds, the 
affect is not as great. 
The manner of administering pGH to the animals can 
be by injectable. The amount of the dosage will vary, 
generally in the range of from 0.5 mg per day to 10 mg 
per day, preferably from 2 mg per day to 8 mg per day. 
Quite satisfactory results are achieved at 4 mg per day. 
The pGH is mixed with normal carrier materials, of 
natural origin and completely non-harmful to the ani-
mal. Such carrier materials may include typical animal 
pharmaceutical carriers such as dextrose, glucose and 
polyhydric alcohols such as sorbitol and mannitol. The 
precise carrier material, where one is employed, is not 
critical and well within the routine skill for selection. 
The following examples are offered to further illus-
trate but not limit the process of the present invention. 
EXAMPLES 
In the following examples, 48 pigs were selected as 
animals for testing. The animals were classified accord-
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ing to their stress genotype. The animals were screened 
by blood typing, CPK testing, and halothane screening. 
Thereafter, the animals were characterized as either 
positive for porcine stress syndrome, as carriers, or as 
negative. After this classification 48 animals were se- 5 
lected for the test and they were evaluated for rate and 
efficiency of gain, leg soundness, muscle quality and 
body composition in response to the administration of 
pGH or porcine somatotropin. The porcine somatotro-
pin used in the testing was obtained from Pitman-Moore 10 
of Terre Haute, Ind. 
In particular, forty-eight cross-bred pigs (24 barrows, 
24 gilts) were allocated to six treatment groups consist-
ing of eight per group. There were 4 barrows and 4 gilts 
in each group. They were segregated in the following 15 
groups, as indicated in Table I below. 
TABLE I 
measurements were made from 24 hours chilled car-
casses and the tenth and eleventh rib longissimus muscle 
sample was collected and utilized for determining mus-
cle quality (color, texture, marbling), muscle reflec-
tance and percent transmittance of light. Muscle reflec-
tance is determined by placing a light reflecting meter 
on the top of a porcine muscle and taking a reading. The 
percent of transmittance is measured by the percent of 
transmission of light through the muscle. Generally, the 
higher the transmission number the less desirable the 
meat quality because it is more pale in color and more 
watery. Likewise, the higher the reflectance the less 
desirable because the meat is paler in color. With regard 
to pH change, the higher the pH the greater the water-
holding capacity of the meat which is of economic 
importance in the processing of the meat. 
Table II shows the mean scores for each of the eight 
animals in the groups. 
TABLE II 
Test Results 
NN NNPST Nn NnPST nn nnPST 
Measurement (N = 8) (n = 8) (h = 8) (n = 8) (n = 8) (n = 7) 
45 Min .• pH 
Reflectance 
%Transmission 
24 Hr. pH 
Treatment Stress-Positive Stress-Carrier Stress-Negative 
PST 8 8 8 
(nn Psn (Nn PST) (NN PST) 30 
Placebo 8 8 8 
(nn) (Nn) (NN) 
6.5 6.5 6.3 6.1 5.6 5.9 
25.1 21.! 27.5 23.9 30.5 25.4 
24.4 !2.4 26.! 24.8 83.9 50.8 
5.5 5. 7 5.5 5.5 5.4 5.5 
As can be seen, the average 45 minute muscle pH was 
similar for both treated and control animals with the 
NN and Nn genotypes, but a positive effect of porcine 
somatotropin on the nn animals was noted. The ultimate 
pH of the NNPST was higher, and differences for 
nnPST were observed. Muscle color approached nor-
mal, and transmittance was lower for nn than NN. Re-
flectance values were reduced for NNPST and nnPST 
groups compared with their respective controls. In 
other tests lower marbling scores tend to occur in the 
treated negative genotypes and lean texture of the loin 
muscle improved in nnPST versus nn. In general, it can 
be seen from the table that administration of porcine 
somatotropin during the critical growth months im-
proved both quality and qualitative carcass characteris-
tics of all genotypes. 
What is claimed is: 
1. A method of improving muscle quality of pigs 
normally susceptible to procine stress syndrome, said 
method comprising: administering daily to said pigs 
during their period of time for critical weight gain, in 
As illustrated in Table I, the forty-eight animals were 
broken into the three genotypes, stress-positive, stress- 35 
carriers, and stress-negative. These animals were in 
groups of eight, with one group being positively treated 
with porcine somatotropin (PST) and with another like 
group of eight being treated with placebo. The placebo 
was a sterile diluent carrier, absent the PST. The pigs 40 
were fed an ad libitum com-soybean diet formulated to 
contain 17.6% protein and 1.2% lysine. Two pigs of the 
same sex and stress classification and treatment were 
housed per pen in a concrete floored confinement build-
ing. Assignment to pens occurred prior to 70 pounds of 45 
average weight but the pigs were not started on the 
treatment of the invention until the total pen weight 
reached 240 pounds indicating the animals' weight aver-
age of 120 pounds. These pigs normally were at about 3 
months of age at this time. 50 conjunction with their daily feed ration a small but 
muscle quality improving effective amount of procine 
somatotropin. 
The pigs began injection with porcine somatotropin 
at 4 rng per head, or with the placebo at the time the 
total pen weight of two pigs each reached 240 pounds. 
The pigs were injected once per day until they were 
taken off of the test. They were taken off of the test 55 
when the weight of each animal reached 240 pounds, 
which was approximately between five and six months 
of age. 
Backfat measurements at the last rib (1-2 inches off 
the midline) were taken with a Renco ultrasonic rna- 60 
chine and the pigs were scored on soundness at the start 
and the end of the test. The porcine somatotropin treat-
ments were terminated at weekly intervals as individual 
pigs reached 240 pounds. The animals were then fed for 
six additional days before slaughter. Forty-five minutes 65 
after slaughter longissimus muscle samples were col-
lected for determination of muscle pH. Standard carcass 
2. The method of claim 1 wherein said administration 
occurs from the live weight of about 120 pounds to a 
live weight of about 240 pounds. 
3. The method of claim 1 wherein the porcine so-
matotropin is a recombinant DNA produced porcine 
somatotropin. 
4. The method of claim 1 wherein the administration 
is by injection. 
5. The method of claim 1 wherein the administration 
is by intramuscular injection. 
6. The method of claim 1 wherein the dosage level is 
from 0.5 rng per day to about 10 rng per day. 
7. The method of claim 6 wherein the dosage level is 
from about 2 rng per day to about 8 mg per day. 
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